InspireMD (NYSE:NSPR) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of InspireMD (NYSE:NSPR) in a report released on Sunday. The brokerage issued a sell rating on the stock.

A number of other equities analysts have also commented on the stock. Piper Sandler restated an “overweight” rating and issued a $4.50 price objective on shares of InspireMD in a research report on Tuesday, September 17th. Lake Street Capital began coverage on shares of InspireMD in a report on Wednesday, December 11th. They issued a “buy” rating and a $5.00 price target for the company.

InspireMD Price Performance

Shares of NSPR stock opened at $2.71 on Friday. The stock has a market capitalization of $70.69 million, a price-to-earnings ratio of -3.61 and a beta of 0.99. The company’s fifty day simple moving average is $2.75 and its two-hundred day simple moving average is $2.70. InspireMD has a 1 year low of $1.81 and a 1 year high of $3.42.

InspireMD (NYSE:NSPR) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.04. InspireMD had a negative return on equity of 69.42% and a negative net margin of 413.96%. The company had revenue of $1.81 million for the quarter, compared to analyst estimates of $1.74 million. During the same period in the previous year, the company posted ($0.15) EPS. Equities research analysts anticipate that InspireMD will post -0.79 EPS for the current year.

Institutional Trading of InspireMD

An institutional investor recently bought a new position in InspireMD stock. Affiance Financial LLC purchased a new position in InspireMD, Inc. (NYSE:NSPR) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 183,746 shares of the company’s stock, valued at approximately $492,000. Affiance Financial LLC owned approximately 0.74% of InspireMD at the end of the most recent reporting period. 44.78% of the stock is currently owned by hedge funds and other institutional investors.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.